Immunological Data Discovery Index
Immunological Data Discovery Index
| identifier: | SDY264 |
| description: |
They found that dendritic cell-activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalenebased oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus.
|
| aggregation: |
instance of dataset
|
| refinement: |
2 - Complete set of descriptive data and results, as ascertained by ImmPort.
|
| availability: |
available with registration
|
| primaryPublications: |
22869731 |
| isAbout: |
Show that dendritic cell-activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalenebased oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus.
|
| authorizations: |
registration required
|
| accessURL: |
https://aspera-immport.niaid.nih.gov:9443/browser?path=SDY264 |
| landingPage: |
http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY264 |
| clinical trial: | |
| study category: | Infection Response |
| study type: | Interventional |
| subject species: | Mus musculus |
| biosample type: |
Other Tissue |
| subject gender: | Unknown |
| assay type: |
ELISPOT Other |
| name: |
mice sequentially exposed to two closely related hemagglutinin 1 neuraminidase 1 (H1N1) influenza strains A/PR/8/34 and A/FM/1/47
|
| fullName: |
Joshy Jacob
|
| affiliations: |
Emory Vaccine Center, Emory University
|
| roles: |
principal investigator
|
| name: |
Strategies to alleviate original antigenic sin
|
| size: |
21
|
| name: |
Influenza Pathogenesis & Immunology Research Center (IPIRC)
|
| output: |
lung viral titers by plaque assay, neutralization titer, ELISPOT assay
|
| studyGroups: |
PBS_PBS_LV.FM1: naive control that received PBS first, a month later PBS, then challenged the mice with 100x LD50 of live mouse-adapted FM1
PBS_WI.FM1_LV.FM1: control group of mice received PBS first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU, immune control), then challenged the mice with 100x LD50 of live mouse-adapted FM1
WI.PR8_WI.FM1_LV.FM1: mice received Whole inactive PR8 (1,400 HAU) first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU), then challenged the mice with 100x LD50 of live mouse-adapted FM2
WI.PR8_WI.FM1.PT_LV.FM1: mice received Whole inactive PR8 (1,400 HAU) first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU) with 250 ng of PT i.p, then challenged the mice with 100x LD50 of live mouse-adapted FM2
WI.PR8_WI.FM1.CpG_LV.FM1: mice received Whole inactive PR8 (1,400 HAU) first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU) with 50 micrograms of CpG s.c., then challenged the mice with 100x LD50 of live mouse-adapted FM2
PBS_LV.FM1_LV.FM1: control group of mice received PBS first and, a month later, were immunized with Whole inactive FM1 (0.1x LD50, immune control), then challenged the mice with 100x LD50 of live mouse-adapted FM1
LV.PR8_LV.FM1_LV.FM1: mice received Whole inactive PR8 (0.1x LD50) first and, a month later, were immunized with Whole inactive FM1 (0.1x LD50), then challenged the mice with 100x LD50 of live mouse-adapted FM2
LV.PR8_LV.FM1.PT_LV.FM1: mice received Whole inactive PR8 (0.1x LD50) first and, a month later, were immunized with Whole inactive FM1 (0.1x LD50) with 250 ng of PT i.p, then challenged the mice with 100x LD50 of live mouse-adapted FM2
LV.PR8_LV.FM1.CpG_LV.FM1: mice received Whole inactive PR8 (0.1x LD50) first and, a month later, were immunized with Whole inactive FM1 (0.1x LD50) with 50 micrograms of CpG s.c., then challenged the mice with 100x LD50 of live mouse-adapted FM2
LV.PR8_LV.FM1.PT_LV.FM1: mice received Whole inactive PR8 (0.1x LD50) with 250 ng of PT i.p, a month later, were immunized with Whole inactive FM1 (0.1x LD50) , then challenged the mice with 100x LD50 of live mouse-adapted FM2
LV.PR8_LV.FM1.CpG_LV.FM1: mice received Whole inactive PR8 (0.1x LD50) with 50 micrograms of CpG s.c., a month later, were immunized with Whole inactive FM1 (0.1x LD50) , then challenged the mice with 100x LD50 of live mouse-adapted FM2
PBS: BALB/c mice (three to four mice/group) got PBS
WI.PR8: BALB/c mice (three to four mice/group) were immunized with 10 micrograms of formalin-inactivated PR8 virus
WI.PR8.PT: BALB/c mice (three to four mice/group) were immunized with 10 micrograms of formalin-inactivated PR8 virus then the mice received 250 ng of PT i.p.
WI.PR8.CpG: BALB/c mice (three to four mice/group) were immunized with 10 micrograms of formalin-inactivated PR8 virus then the mice received 50 micrograms of CpG s.c.
WI.PR8_WI.FM1.NE_LV.FM1: BALB/c mice (5-10 mice/group) were sequentially immunized (i.m.) with 1,400 HAU PR8, and then with FM1 mixed with oil-in-water emulsion (NE) at a 1:1 ratio immediately before injection. The mice were lethally challenged with live FM1
WI.PR8.NE_WI.FM1_LV.FM1: BALB/c mice (5-10 mice/group) were sequentially immunized (i.m.) with 1,400 HAU PR8 mixed with oil-in-water emulsion (NE) at a 1:1 ratio immediately before injection, and then with FM1. The mice were lethally challenged with live FM1
PBS_WI.FM1.HA_FM1.AG: Mice sequentially immunized with PBS then FM1-HA using a gene gun, then boosted these mice with the same dose of FM1 Ag one month later
WI.PR8.HA_WI.FM1.HA_LV.FM1: Mice sequentially immunized with HA-encoding DNA vaccines 2 ?g PR8-HA then FM1-HA using a gene gun, then boosted these mice with the same dose of FM1 Ag one month later
PBS_WI.FM1_FM1.AG: mice received PBS first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU), then boosted these mice with 2 micrograms of FM1 Ag one month later
WI.PR8_WI.FM1_FM1.AG: mice were immunized with Whole inactive PR8 (1,400 HAU) first and, a month later, were immunized with Whole inactive FM1 (1,400 HAU), then boosted these mice with 2 micrograms of FM1 Ag one month later
|
| description: |
They explored strategies to overcome original antigenic sin responses in mice sequentially exposed to two closely related H1N1 influenza strains A/PR/8/34 and A/FM/1/47.
|
| identifier: |
10.21430/M3EQ20FG3W
|
| name: |
ImmPort
|
| identifier: |
SCR:012804
|
| homePage: |
http://www.immport.org |
